{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Vaccine+2&page=5",
    "query": {
      "intervention": "Control Vaccine 2",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 680,
    "total_pages": 68,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Vaccine+2&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Vaccine+2&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-17T04:19:04.802Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03002324",
      "title": "Tailoring of Vaccine-Focused Messages: Disease Salience",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Human Papillomavirus"
      ],
      "interventions": [
        {
          "name": "Baseline Survey",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Current CDC Message",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Cervical Cancer Message",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Control Message",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Post-Intervention Survey",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1320,
      "start_date": "2017-01",
      "completion_date": "2017-05-01",
      "has_results": false,
      "last_update_posted_date": "2017-05-10",
      "last_synced_at": "2026-10-17T04:19:04.802Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03002324"
    },
    {
      "nct_id": "NCT06926062",
      "title": "Interpersonal Communication Training and Vaccination Workflow Training Alone and in Combination to Improve Communication and Recommendations About HPV Vaccination in Pharmacies, IMPACT HPV Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Human Papillomavirus-Related Carcinoma"
      ],
      "interventions": [
        {
          "name": "Best Practice",
          "type": "OTHER"
        },
        {
          "name": "Educational Intervention",
          "type": "OTHER"
        },
        {
          "name": "Interview",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Training and Education",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Vaccination",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BEHAVIORAL",
        "PROCEDURE"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1900,
      "start_date": "2026-10-15",
      "completion_date": "2027-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-17",
      "last_synced_at": "2026-10-17T04:19:04.802Z",
      "location_count": 2,
      "location_summary": "University Park, Pennsylvania • Seattle, Washington",
      "locations": [
        {
          "city": "University Park",
          "state": "Pennsylvania"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06926062"
    },
    {
      "nct_id": "NCT04469179",
      "title": "Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COVID-19",
        "SARS-CoV2"
      ],
      "interventions": [
        {
          "name": "SAB-185",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Normal Saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "SAb Biotherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 21,
      "start_date": "2020-08-20",
      "completion_date": "2021-11",
      "has_results": false,
      "last_update_posted_date": "2021-10-26",
      "last_synced_at": "2026-10-17T04:19:04.802Z",
      "location_count": 3,
      "location_summary": "Miami Beach, Florida • Omaha, Nebraska • Sioux Falls, South Dakota",
      "locations": [
        {
          "city": "Miami Beach",
          "state": "Florida"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Sioux Falls",
          "state": "South Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04469179"
    },
    {
      "nct_id": "NCT03512288",
      "title": "Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pneumococcal Infections"
      ],
      "interventions": [
        {
          "name": "Multivalent",
          "type": "BIOLOGICAL"
        },
        {
          "name": "13vPnC",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "42 Days",
        "maximum_age": "98 Days",
        "sex": "ALL",
        "summary": "42 Days to 98 Days"
      },
      "enrollment_count": 460,
      "start_date": "2018-04-16",
      "completion_date": "2020-02-11",
      "has_results": true,
      "last_update_posted_date": "2021-03-02",
      "last_synced_at": "2026-10-17T04:19:04.802Z",
      "location_count": 39,
      "location_summary": "Fayetteville, Arkansas • Downey, California • Huntington Beach, California + 29 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Ontario",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03512288"
    },
    {
      "nct_id": "NCT07734649",
      "title": "Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Immunization",
        "Human Metapneumovirus Immunization",
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "RSV+HMPV vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Control Vaccine 3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Control Vaccine 4",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Control Vaccine 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Control Vaccine 1",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 2400,
      "start_date": "2026-07-22",
      "completion_date": "2028-05-03",
      "has_results": false,
      "last_update_posted_date": "2026-10-14",
      "last_synced_at": "2026-10-17T04:19:04.802Z",
      "location_count": 50,
      "location_summary": "Gadsden, Alabama • Vestavia Hills, Alabama • Huntington Beach, California + 43 more",
      "locations": [
        {
          "city": "Gadsden",
          "state": "Alabama"
        },
        {
          "city": "Vestavia Hills",
          "state": "Alabama"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07734649"
    },
    {
      "nct_id": "NCT03409276",
      "title": "Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "env (A,B,C,A/E)/gag (C) DNA Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "gp120 (A,B,C,A/E) Protein Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GLA-SE adjuvant",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 60,
      "start_date": "2018-03-16",
      "completion_date": "2020-10-22",
      "has_results": true,
      "last_update_posted_date": "2022-04-25",
      "last_synced_at": "2026-10-17T04:19:04.802Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Decatur, Georgia • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03409276"
    },
    {
      "nct_id": "NCT07095868",
      "title": "Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Selected Types of Solid Tumor"
      ],
      "interventions": [
        {
          "name": "EVM14",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Everest Medicines (Beijing) Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 94,
      "start_date": "2025-11-17",
      "completion_date": "2031-11",
      "has_results": false,
      "last_update_posted_date": "2026-08-04",
      "last_synced_at": "2026-10-17T04:19:04.802Z",
      "location_count": 3,
      "location_summary": "New York, New York • Houston, Texas • Fairfax, Virginia",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07095868"
    },
    {
      "nct_id": "NCT07013747",
      "title": "Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acne"
      ],
      "interventions": [
        {
          "name": "Acne mRNA vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 228,
      "start_date": "2025-07-03",
      "completion_date": "2030-03-13",
      "has_results": false,
      "last_update_posted_date": "2026-07-09",
      "last_synced_at": "2026-10-17T04:19:04.802Z",
      "location_count": 4,
      "location_summary": "Encino, California • Brandon, Florida • Jacksonville, Florida + 1 more",
      "locations": [
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Brandon",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07013747"
    },
    {
      "nct_id": "NCT02362451",
      "title": "Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men With Stage D0 Prostate Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostatic Neoplasms",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Autologus elutriated monocyte placebo vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Multi-epitope (ME) T-cell receptor g alternate reading frame protein (TARP) vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 7,
      "start_date": "2015-07-10",
      "completion_date": "2020-02-13",
      "has_results": true,
      "last_update_posted_date": "2022-03-18",
      "last_synced_at": "2026-10-17T04:19:04.802Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02362451"
    },
    {
      "nct_id": "NCT00679172",
      "title": "Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Typhoid"
      ],
      "interventions": [
        {
          "name": "Dose of 5.0 x 10^9 CFU (Cohort 1)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Dose of 7.5 x 10^9 CFU (Cohort 2)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Dose of 1.1 x 10^10 CFU (Cohort 3)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Dose of of 1.7 x 10^10 CFU (Cohort 4)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (Cohorts 1-4 pooled)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Emergent BioSolutions",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 187,
      "start_date": "2008-05",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2024-04-09",
      "last_synced_at": "2026-10-17T04:19:04.802Z",
      "location_count": 3,
      "location_summary": "South Miami, Florida • Baltimore, Maryland • Burlington, Vermont",
      "locations": [
        {
          "city": "South Miami",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Burlington",
          "state": "Vermont"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00679172"
    }
  ]
}